Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) was the recipient of a large increase in short interest during the month of May. As of May 30th, there was short interest totalling 965,776 shares, an increase of 30.4% from the May 15th total of 740,868 shares, Stock Ratings Network.com reports. Based on an average trading volume of 677,178 shares, the short-interest ratio is presently 1.4 days. Currently, 6.9% of the company’s shares are short sold.

Several analysts have recently commented on the stock. Analysts at Summer Street initiated coverage on shares of Intercept Pharmaceuticals in a research note on Thursday, May 15th. They set a “buy” rating and a $650.00 price target on the stock. Separately, analysts at Oppenheimer cut their price target on shares of Intercept Pharmaceuticals from $525.00 to $499.00 in a research note on Thursday, May 8th. They now have an “outperform” rating on the stock. Finally, analysts at Needham & Company LLC reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $585.67.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 280.50 on Wednesday. Intercept Pharmaceuticals has a 52-week low of $35.00 and a 52-week high of $497.00. The stock’s 50-day moving average is $256. and its 200-day moving average is $265.5. The company’s market cap is $5.915 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.87. On average, analysts predict that Intercept Pharmaceuticals will post $-13.40 earnings per share for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.